These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2232491)

  • 61. Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin.
    Watson AJ; Gimenez LF; Cotton S; Walser M; Spivak JL
    Am J Med; 1990 Oct; 89(4):432-5. PubMed ID: 2220877
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval.
    Powe NR; Griffiths RI; de Lissovoy G; Anderson GF; Watson AJ; Greer JW; Herbert RJ; Eggers PW; Milam RA; Whelton PK
    JAMA; 1992 Sep; 268(11):1434-40. PubMed ID: 1512912
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Serum soluble interleukin 2 receptor in hemodialysis patients treated with recombinant human erythropoietin.
    Sennesael JJ; Demanet CG; Verbeelen DL
    Blood Purif; 1995; 13(6):347-56. PubMed ID: 8821199
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [The importance of erythropoietin in the therapy of anemia in patients on chronic hemodialysis].
    von Appen K; Klinkmann H
    Urol Nefrol (Mosk); 1990; (6):69-70. PubMed ID: 2089771
    [No Abstract]   [Full Text] [Related]  

  • 65. Effect of recombinant human erythropoietin administration on immunological indices in patients undergoing chronic hemodialysis.
    Yorioka N; Hamaguchi N; Takasugi N; Shigemoto K; Harada S; Fujiwara K; Ishida A; Maeda T; Kawai A; Yamakido M
    Nihon Jinzo Gakkai Shi; 1993 Aug; 35(8):981-8. PubMed ID: 8255010
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990-1996.
    Cotter DJ; Thamer M; Kimmel PL; Sadler JH
    Kidney Int; 1998 Dec; 54(6):2129-39. PubMed ID: 9853279
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.
    Pérez-Oliva JF; Casanova-González M; García-García I; Porrero-Martín PJ; Valenzuela-Silva CM; Hernández-Montero T; Lagarde-Ampudia M; Casanova-Kutsareva Y; Avila-Albuerne Y; Vargas-Batista A; Bobillo-López H; Herrera-Valdés R; López-Saura PA;
    BMC Nephrol; 2005 May; 6():5. PubMed ID: 15910687
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Mathematical approach for estimating iron needs in hemodialysis patients on erythropoietin therapy.
    Tarng DC; Huang TP; Chen TW
    Am J Nephrol; 1997; 17(2):158-64. PubMed ID: 9096447
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effect of Predialysis Recombinant Human Erythropoietin on Early Survival After Hemodialysis Initiation in Patients With Chronic Kidney Disease: Co-JET Study.
    Watanabe Y; Akizawa T; Saito A; Gejyo F; Suzuki M; Nishizawa Y; Tomino Y; Tsubakihara Y; Akiba T; Hirakata H; Kawanishi H; Bessho M; Udagawa Y; Aoki K; Uemura Y; Ohashi Y;
    Ther Apher Dial; 2016 Dec; 20(6):598-607. PubMed ID: 27928910
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Impacts of recombinant human erythropoietin treatment during predialysis periods on the progression of chronic kidney disease in a large-scale cohort study (Co-JET study).
    Akizawa T; Saito A; Gejyo F; Suzuki M; Nishizawa Y; Tomino Y; Tsubakihara Y; Akiba T; Hirakata H; Watanabe Y; Kawanishi H; Bessho M; Udagawa Y; Aoki K; Uemura Y; Ohashi Y;
    Ther Apher Dial; 2014 Apr; 18(2):140-8. PubMed ID: 24720404
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Treatment of anemia in patients with chronic renal insufficiency undergoing hemodialysis with recombinant human erythropoietin: 12 months' experience].
    de Sousa FT; Prata MM; Barbas JV; dos Santos JP
    Acta Med Port; 1990; 3(6):347-52. PubMed ID: 2089856
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Correction of copper deficiency improves erythropoietin unresponsiveness in hemodialysis patients with anemia.
    Higuchi T; Matsukawa Y; Okada K; Oikawa O; Yamazaki T; Ohnishi Y; Fujita T; Fukuda N; Soma M; Matsumoto K
    Intern Med; 2006; 45(5):271-3. PubMed ID: 16595992
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Is it time for a paradigm shift? Is erythropoietin deficiency still the main cause of renal anaemia?
    Eschbach JW; Varma A; Stivelman JC
    Nephrol Dial Transplant; 2002; 17 Suppl 5():2-7. PubMed ID: 12091599
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Treatment of anemia with recombinant human erythropoietin and the bone marrow response in uremic patients undergoing periodic hemodialysis].
    García Martín F; Carrascosa Vallejo T; Martín Escobar E; Val Begueria J; Martín Hernández R; de Arriba G; Teno C; Salvatierra J
    Rev Clin Esp; 1990 May; 186(9):419-22. PubMed ID: 2247677
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effect on hemoglobin F synthesis by erythropoietin in patients with anemia of end-stage renal disease maintained by chronic hemodialysis.
    Salvati F; Strippoli P; Barchetti M; Scatizzi A
    Nephron; 1992; 60(3):371. PubMed ID: 1373475
    [No Abstract]   [Full Text] [Related]  

  • 76. Human recombinant erythropoietin (rHuEPO) in the treatment of anemia in patients with chronic renal failure (CRF): experience with a group of patients on chronic haemodialysis treatment.
    Ramírez B; Flores A; Pérez F; Córdoba C; García L; Vázquez G
    Transplant Proc; 1991 Apr; 23(2):1833-4. PubMed ID: 2053170
    [No Abstract]   [Full Text] [Related]  

  • 77. Use of subcutaneous recombinant human erythropoietin in children undergoing continuous cycling peritoneal dialysis.
    Sinai-Trieman L; Salusky IB; Fine RN
    J Pediatr; 1989 Apr; 114(4 Pt 1):550-4. PubMed ID: 2926567
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Effect of recombinant human erythropoietin (rEPO) on angina pectoris in patients with chronic maintenance hemodialysis].
    Imamura Y; Hase H
    Nihon Jinzo Gakkai Shi; 1991 Apr; 33(4):403-8. PubMed ID: 1875559
    [TBL] [Abstract][Full Text] [Related]  

  • 79. How erythropoietin affects bone marrow of uremic patients.
    Sikole A; Stojanovic A; Polenakovic M; Petrusevska G; Sadikario S; Saso R; Jovanovski M
    Am J Nephrol; 1997; 17(2):128-36. PubMed ID: 9096443
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cognitive function, mood and P3 latency: effects of the amelioration of anemia in dialysis patients.
    Brown WS; Marsh JT; Wolcott D; Takushi R; Carr CR; Higa J; Nissenson AR
    Neuropsychologia; 1991; 29(1):35-45. PubMed ID: 2017307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.